Evidence map›Paper›PMID 20659975›Full record

ArticleDevelopment (Cambridge, England)2010

Temporal specification of blood progenitors from mouse embryonic stem cells and induced pluripotent stem cells.

Stefan Irion, Raedun L Clarke, Hervé Luche, Injune Kim, Sean J Morrison, Hans-Joerg Fehling, Gordon M Keller

Open access · greenAbstract read
In one paragraph

Article in Development (Cambridge, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Earlier and broader roles of Mesp1 in cardiovascular development.Cellular and molecular life sciences : CMLS · 2017
    Review
  14. Review
  15. Article
  16. Checkpoints that control B cell development.The Journal of clinical investigation · 2015
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Stefan IrionMcEwen Centre for Regenerative Medicine, University Health Network, Toronto, ON, Canada.
Raedun L Clarke
Hervé Luche
Injune Kim
Sean J Morrison
Hans-Joerg Fehling
Gordon M Keller
Korea Advanced Institute of Science and Technology · KRUniversity of Michigan–Ann Arbor · US

Funding

IDENTIFICATION &CHARACTERIZATION OF HEMANGIOBLASTR01HL048834 · NHLBI · NATIONAL JEWISH HEALTH · PI KELLER, GORDON · 1994 to 2006
$3.0M
NHLBI NIH HHS R01 HL048834NHLBI NIH HHS R01 HL 48834-09
6 · The paper itself

Abstract

The efficient and reproducible generation of differentiated progenitors from pluripotent stem cells requires the recapitulation of appropriate developmental stages and pathways. Here, we have used the combination of activin A, BMP4 and VEGF under serum-free conditions to induce hematopoietic differentiation from both embryonic and induced pluripotent stem cells, with the aim of modeling the primary sites of embryonic hematopoiesis. We identified two distinct Flk1-positive hematopoietic populations that can be isolated based on temporal patterns of emergence. The earliest arising population displays characteristics of yolk sac hematopoiesis, whereas a late developing Flk1-positive population appears to reflect the para-aortic splanchnopleura hematopoietic program, as it has reduced primitive erythroid capacity and substantially enhanced myeloid and lymphoid potential compared with the earlier wave. These differences between the two populations are accompanied by differences in the expression of Sox17 and Hoxb4, as well as in the cell surface markers AA4.1 and CD41. Together, these findings support the interpretation that the two populations are representative of the early sites of mammalian hematopoiesis.

Indexed as

ActivinsAnimalsBone Morphogenetic Protein 4Cell DifferentiationCell LineEmbryonic Stem CellsGene ExpressionHematopoiesisHematopoietic Stem CellsHMGB ProteinsHomeodomain ProteinsLymphopoiesisMembrane GlycoproteinsMiceModels, BiologicalPlatelet Membrane Glycoprotein IIbactivin AActivinsBMP4 protein, humanBone Morphogenetic Protein 4complement 1q receptorHMGB ProteinsHomeodomain ProteinsHoxb4 protein, mouseMembrane GlycoproteinsPlatelet Membrane Glycoprotein IIbReceptors, ComplementRecombinant ProteinsSox17 protein, mouseSOXF Transcription FactorsTranscription FactorsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2VEGFA protein, human

Identifiers

PMID20659975
PMCPMC2938916
OpenAlexW2166688933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.